Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: surelock who wrote (10675)	11/4/2002 10:38:13 AM
From: afrayem onigwecher	Respond to of 19428

GENEMAX CORP - FEATURED IN 'BUSINESS WEEK' It has been somewhat painful for us to watch the meteoric rise in GeneMax shares since we first released the OTC Digest Featured Company Profile on August 14th since we are obligated contractually and ethically to refrain from any market activity in GMXX shares. Simply put, we must stand on the sidelines and do nothing. Fortunately, the beneficiary of our dilemma is you, our valued Member. Those OTC Digest Members who swallowed hard, heeded our call, and took a stake in GMXX shares, congratulations! In two months, the hard-earned dollars you were willing to speculate with have likely produced close to a triple-digit return. It pays to be in the know with The OTC Digest. Why? For those with a higher threshold it appears likely there may be more on the upside for GeneMax, based on a just released 'Business Week' article. This type of 'Tier One' press can only help GMXX shares. For those registered online with Business Week you can view the article now in the 'Developments To Watch' section. The print version will be available on shelves this Monday November 4th. The day after our original profile (August 15th) GMXX shares closed at $3.82. The closing quote that day however, was $4.25 bid-$4.40 ask. We believed strongly at the time (and have been vindicated in that belief) that specific legal action taken by the Company to ensure fair market trading of GMXX shares would eventually create natural buying pressure. Since then, it appears that at least two market makers trading illegally in GMXX shares have closed their doors. GMXX rallied nearly 15% the day after our release, and the stock has hardly looked back since. In the face of this long-in-the-tooth-bear-market, please allow us to be first to recite the old stockbroker's adage, "Stocks go up...and stocks go down." True to form by October 2, GMXX hit a yearly high of $9.40 before profit taking finally halted the huge two-month rally. The stock pulled back to a closing low of $5.15 by mid October. GMXX shares have since worked higher again. GeneMax drifted back up to close at $8.55 on trading of 143,000 shares by the close of trading on Halloween. Not to be lost is the fact that the Company made some noteworthy fundamental progress during this period. GeneMax announced two important additions to their Scientific Advisory Board last month. On October 14th, Dr. Soldano Ferrone M.D., Ph.D. and Chairman of the Immunology Department at the Roswell Park Cancer Institute in New York agreed to join the GeneMax scientific team. Dr. Ferrone is a renowned immunologist and believes GeneMax' TAP technology could one day have a profound effect on the treatment of various forms of cancer. Thursday, Genemax announced that Dr. Barbara Seliger has joined their Scientific Advisory Board. Dr. Seliger is Professor of Immunology and Pathophysiology at the Johannes Gutenberg University, Department of Internal Medicine in Mainz, Germany. Dr. Seliger is a world expert in tumor biology, tumor immunology and immunotherapy. She has worked on TAP (transporters associated with antigen processing, Genemax' specific area of interest) and in HLA class I antigen down regulation in human cancers. Here's what Dr. Seliger said in conjunction with her appointment to the GeneMax Scientific Advisory Board: "I believe that GeneMax's core technologies involving TAP are entirely innovative and have the potential to alter the course of immunotherapies for tumors and other areas as well. It is a privilege to be involved in this ground breaking work and to help facilitate the upcoming clinical trials." If you missed the OTC Digest profile on GeneMax, we urge you to review it today by clicking here. OTC Digest Members who haven't contacted GMXX yet, are strongly urged to request your own due diligence package on this well-managed biotechnology company. To obtain more information and or receive updates on GeneMax Corp., please click here. Thank you for being a Member of the OTC Digest! Feel free to tell a friend about us! We'd like to welcome more people like you to the OTC Digest! otcdigest.com